Pazopanib is a small multi-targeted tyrosine kinase inhibitor (TKI) against VEGFR1, VEGFR2, VEGFR3, and PDGFR, which is approved for the treatment of metastatic STS after anthracycline-based chemotherapy, or in the first line of treatment in patients not eligible for this therapy [105]. The gene discussed is PDGFRB; the disease is telomere syndrome.